Cardiopulmonary Exercise Testing: Pulmonary Hypertension

心肺运动测试：肺动脉高压

• 批准号: 7013623
• 负责人: RONALD J. OUDIZ
• 金额: $ 13.42万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-02-01 至 2008-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7013623
• 关键词: Cardiopulmonary; Exercise; Testing; Pulmonary; Hypertension

(Revised Abstract) Description: Pulmonary arterial hypertension (PAH) is a devastating, rapidly progressive disease of the pulmonary vasculature that typically affects young women between the ages of 21 and 40. Untreated, the median survival time is 2.8 years. Only lung transplantation relieves the pulmonary hypertension. Methods currently used to assess the clinical course are either subjective or do not correlate well with symptoms and life expectancy. Right heart catheterization is widely-used to measure disease severity and response to therapy, but repeated catheterization causes morbidity and is a potential barrier to needed changes in therapy. Also, catheterization is performed at rest, not during exercise, when the patient is symptomatic. In contrast, preliminary data from the PI and his mentor show that noninvasive measures of aerobic function and ventilatory efficiency during exercise are closely related to disease severity and response to therapy in patients with PAH. This has broad implications for determining prognosis, selection of treatment, and making decisions on the timing of lung transplantation. The broad objectives of this proposal are to define optimal methods for noninvasively assessing patients with PAH, and to develop a prognostic model using cardiopulmonary exercise testing (CPET). The specific aims are: 1) To establish peak exercise oxygen consumption (peak VOz) and other CPET measurements as independent predictors of survival time, need for tung transplantation, or hospitalization for symptoms of PAH. 2) To use CPET parameters to further subclassify patients with NYHA II and III functional class symptoms, and patients with 6-minute walk distances of 250-400 m 3) To establish the relationship between peak VO2 and other CPET measurements in tracking the response to vasodilator therapy. This study will help determine the most useful parameter(s) to follow for making critical clinical decisions, including determining the need for and timing of lung transplantation. From our large PAH referral clinic, we will perform CPET in 72 human subjects with PAH, as defined by the World Health Organization. We will examine how the pulmonary vasculopathy of PAH affects exercise aerobic capacity and ventilatory efficiency in PAH, and how these important reflections of cardiac and pulmonary vascular function relate to clinical indices used in the conventional evaluation of these patients. Our hypotheses are based on the concept that CPET measurements provide objective, quantitative measures of disease severity and response to therapy. Therefore important therapeutic decisions can be based on objective measures of the circulatory and ventilatory responses to exercise, This proposal will enable the PI to participate in a structured, graded career development program leading to the acquisition of skills needed for a career in patient-oriented cardiovascular research.

描述：肺动脉高压（PAH）是一种破坏性的、快速进展的肺血管疾病，通常影响21至40岁的年轻女性。未经治疗，中位生存时间为2.8年。只有肺移植才能缓解肺动脉高压。目前用于评估临床病程的方法要么是主观的，要么与症状和预期寿命没有很好的相关性。右心导管被广泛用于测量疾病的严重程度和对治疗的反应，但反复导管会导致发病率，并且是治疗所需改变的潜在障碍。此外，当患者有症状时，应在休息时进行导尿，而不是在运动时。相比之下，来自PI和他的导师的初步数据显示，运动过程中有氧功能和通气效率的无创测量与PAH患者的疾病严重程度和对治疗的反应密切相关。这对确定预后、选择治疗方法和决定肺移植的时机具有广泛的意义。本提案的主要目标是确定无创评估PAH患者的最佳方法，并利用心肺运动试验（CPET）建立预后模型。具体目的是：1)建立峰值运动耗氧量（峰值VOz）和其他CPET测量值作为生存时间、tung移植需求或PAH症状住院治疗的独立预测因子。2)利用CPET参数进一步对NYHA II和III功能级症状患者以及6分钟步行距离为250-400 m的患者进行亚分类。3)建立VO2峰值与其他CPET测量值在追踪血管扩张剂治疗反应中的关系。这项研究将有助于确定最有用的